| [1] | MAIDA C D, NORRITO R L, DAIDONE M, et al. Neuroinflammatory mechanisms in ischemic stroke: focus on cardioembolic stroke, background, and therapeutic approaches [J]. Int J Mol Sci, 2020, 21(18): E6454. doi: 10.3390/ijms21186454 |
| [2] | 王陇德, 彭斌, 张鸿祺, 等. 《中国脑卒中防治报告2020》概要[J]. 中国脑血管病杂志, 2022, 19(2): 136-144. |
| [3] | POWERS W J, RABINSTEIN A A, ACKERSON T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association/American stroke association [J]. Stroke, 2019, 50(12): e344-e418. |
| [4] | SUGUNARAJ J P, PALANISWAMY C, SELVARAJ D R, et al. Clopidogrel resistance [J]. Am J Ther, 2010, 17(2): 210-215. doi: 10.1097/MJT.0b013e3181bdc3e4 |
| [5] | ZOU X, DENG X L, WANG Y M, et al. Genetic polymor-phisms of high platelet reactivity in Chinese patients with coronary heart disease under clopidogrel therapy[J]. Int J Clin Pharm, 2020, 42((1):): 158-166. doi: 10.1007/s11096-019-00953-w |
| [6] | AL-HUSEIN B A, AL-AZZAM S I, ALZOUBI K H, et al. Investigating the effect of demographics, clinical characteristics, and polymorphism of MDR-1, CYP1A2, CYP3A4, and CYP3A5 on clopidogrel resistance[J]. J Cardiovasc Pharmacol, 2018, 72(6): 296-302. doi: 10.1097/FJC.0000000000000627 |
| [7] | WU Z K, WANG J J, WANG T, et al. Clopidogrel resistance response in patients with coronary artery disease and metabolic syndrome: the role of hyperglycemia and obesity[J]. J Geriatr Cardiol, 2015, 12(4): 378-382. |
| [8] | SU J F, HU X H, LI C Y. Risk factors for clopidogrel resis-tance in patients with ischemic cerebral infarction and the correlation with ABCB1 gene rs1045642 polymorphism[J]. Exp Ther Med, 2015, 9((1):): 267-271. doi: 10.3892/etm.2014.2058 |
| [9] | LI J, WANG Y, LI H, et al. Homocysteine level predicts response to dual antiplatelet in women with minor stroke or transient ischemic attack: subanalysis of the CHANCE trial[J]. Arterioscler Thromb Vasc Biol, 2020, 40(3): 839-846. doi: 10.1161/ATVBAHA.119.313741 |
| [10] | GALEAZZI R, OLIVIERI F, SPAZZAFUMO L, et al. Clustering of ABCB1 and CYP2C19 genetic variants predicts risk of major bleeding and thrombotic events in elderly patients with acute coronary syndrome receiving dual antiplatelet therapy with aspirin and clopidogrel[J]. Drugs Aging, 2018, 35(7): 649-656. doi: 10.1007/s40266-018-0555-1 |
| [11] | 刘亚巍, 赵小朗, 姚璞, 等. ABCB1、CYP2C19、CES1基因多态性与缺血性脑卒中患者氯吡格雷抵抗及疗效的关系[J]. 中国神经免疫学和神经病学杂志, 2021, 28(2): 146-151. |
| [12] | Bergmeijer T O, Reny J L, Pakyz R E, et al. Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)[J]. Am Heart J, 2018, 198 (10): 152-159. |
| [13] | Mansuy D, Dansette P M. Sulfenic acids as reactive interme-diates in xenobiotic metabolism[J]. [J]. Arch Biochem Biophys, 2011, 507((1):): 174-185. doi: 10.1016/j.abb.2010.09.015 |
| [14] | 钟迪, 张舒婷, 吴波. 《中国急性缺血性脑卒中诊治指南2018》解读[J]. 中国现代神经疾病杂志, 2019, 19(11): 897-901. |
| [15] | LE QUELLEC S, BORDET J C, NEGRIER C, et al. Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature [J]. Thromb Haemost, 2016, 116(4): 638-650. |
| [16] | SHANKER J, GASPARYAN A Y, KITAS G D, et al. Platelet function and antiplatelet therapy in cardiovascular disease: implications of genetic polymorphisms[J]. Curr Vasc Pharmacol, 2011, 9(4): 479-489. doi: 10.2174/157016111796197224 |
| [17] | ZIEGLER S, SCHILLINGER M, FUNK M, et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease [J]. Stroke, 2005, 36(7): 1394-1399. doi: 10.1161/01.STR.0000169922.79281.a5 |
| [18] | QURESHI Z, HOBSON A R. Clopidogrel “resistance”: where are we now? [J]. Cardiovasc Ther, 2013, 31(1): 3-11. doi: 10.1111/j.1755-5922.2011.00296.x |
| [19] | 杨雅薇, 李攀, 陈韬, 等. 四种氯吡格雷抗血小板功能检测方法的比较[J]. 第二军医大学学报, 2016, 37(8): 1002-1006. |
| [20] | 周红, 覃少东, 黄澄. 血栓弹力图在急性脑梗死患者诊疗中的应用进展[J]. 微量元素与健康研究, 2021, 38(1): 68-70. |
| [21] | SUN Y F, VENUGOPAL J, GUO C A, et al. Clopidogrel resis-tance in a murine model of diet-induced obesity is mediated by the interleukin-1 receptor and overcome with DT-678[J]. Arterioscler Thromb Vasc Biol, 2020, 40((6):): 1533-1542. doi: 10.1161/ATVBAHA.120.314146 |
| [22] | ZHOU M C, CAO S P, ZHONG H L, et al. Subacute stent thrombosis in a patient with type 2 diabetes and clopidogrel resistance: a case report[J]. Int J Clin Pharmacol Ther, 2020, 58(8): 449-453. doi: 10.5414/CP203547 |
| [23] | ANGIOLILLO D J, JAKUBOWSKI J A, FERREIRO J L, et al. Impaired responsiveness to the platelet P2Y12 receptor antago-nist clopidogrel in patients with type 2 diabetes and coronary artery disease[J]. J Am Coll Cardiol, 2014, 64((10):): 1005-1014. doi: 10.1016/j.jacc.2014.06.1170 |
| [24] | HU L, TANG Y, SHENG X H, et al. Anti-platelet therapy in mild cerebral infarction patients on the basis of CYP2C19 metabolizer status[J]. Cell Transplant, 2019, 28(8): 1039-1044. doi: 10.1177/0963689719851769 |
| [25] | ANGIOLILLO D J, BERNARDO E, ZANONI M, et al. Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease[J]. J Am Coll Cardiol, 2011, 58(1): 30-39. doi: 10.1016/j.jacc.2011.02.040 |
| [26] | GATOPOULOU A, PAPANAS N, MALTEZOS E. Diabetic gastrointestinal autonomic neuropathy: current status and new achievements for everyday clinical practice [J]. Eur J Intern Med, 2012, 23(6): 499-505. doi: 10.1016/j.ejim.2012.03.001 |
| [27] | OSMANCIK P, PAULU P, TOUSEK P, et al. High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel [J]. J Thromb Thrombolysis, 2012, 33(4): 349-354. doi: 10.1007/s11239-011-0659-5 |
| [28] | 谢文剑, 黄贝贝, 殷蒨, 等. lncRNA在冠心病氯吡格雷抵抗患者中的差异性表达[J]. 中南大学学报(医学版), 2019, 44(1): 9-13. |
| [29] | TUTTOLOMONDO A, DI RAIMONDO D, DI SCIACCA R, et al. Inflammatory cytokines in acute ischemic stroke [J]. Curr Pharm Des, 2008, 14(33): 3574-3589. doi: 10.2174/138161208786848739 |
| [30] | RAMAWAT B, SALUJA A, BHATACHARJEE J, et al. Acute ischemic stroke is associated with increased serum levels of pro-inflammatory cytokines [J]. Indian J Clin Biochem, 2021, 36(3): 380-381. doi: 10.1007/s12291-020-00892-8 |